Table 1. Findings of gene sequencing during treatment.
| Time of sampling | Method | Sample | Gene | Mutation style | Frequency or CN |
|---|---|---|---|---|---|
| Before using EGFR-TKI | 8-gene panel NGS | FFPE | EGFR | Exon 19 deletion | 14.85% |
| After using gefitinib | ddPCR | cfDNA (liquid biopsy) | EGFR | Exon 20 T790M (−) | – |
| 9-gene panel NGS | cfDNA (liquid biopsy) | EGFR | Exon 19 deletion | 1.6% | |
| TP53 | p.K132R | 0.64% | |||
| After using bevacizumab + carboplatin + pemetrexed | 56-gene panel NGS | FFPE | EGFR | Exon 19 deletion | 26.02% |
| TP53 | p.K132R | 51.12% | |||
| EGFR | Amplification | CN =15.48 | |||
| mTOR | p.G28V | 62.79% | |||
| BRCA2 | p.E2355K | 70.17% | |||
| After using bevacizumab + sindilimab | 9-gene panel NGS | cfDNA (liquid biopsy) | EGFR | Exon 19 deletion | 8.2% |
| Exon 20 T790M (+) | 11.6% | ||||
| TP53 | p.K132R | 1.7% | |||
| After using osimertinib | 1021-gene panel NGS | FFPE+ blood | TMB | – | 3.84 Muts/Mb |
| MSI | MSS | – | |||
| EGFR | Exon19 deletion | 30.8% | |||
| Exon 20 T790M (+) | 14.1% | ||||
| BRAF | BTN2A1-BRAF fusion | 9.1% | |||
| TP53 | p.K132R | 30% | |||
| TGFBR1 | p.D104Y | 12.8% | |||
| MYC | Amplification | CN =7.4 | |||
| FANCG | Amplification | CN =6.8 | |||
| IHC | FFPE | PD-L1 | PD-L1 (+) | 90% |
CN, copy number; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NGS, next generation sequencing; FFPE, formaldehyde fixed paraffin embedded; ddPCR, droplet digital polymerase chain reaction; cfDNA, cell free DNA; TMB, tumor mutational burden; MSI, microsatellite instability; MSS, microsatellite stability; IHC, immunohistochemistry; PD-L1, programmed cell death-ligand 1.